ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1098

Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

Kelly Tran1, Ellen Ann Sockman1, Rachel Salyer1, Megan Young1, Aisha Abbasi1 and Devanshu Verma2, 1West Virginia University Hospital, Morgantown, WV, 2West Virginia University, Morgantown, WV

Meeting: ACR Convergence 2023

Keywords: Dual energy x-ray absorptiometry (DEXA), giant cell arteritis, osteoporosis, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1082–1099) Measures & Measurement of Healthcare Quality Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5 million fractures in the United States annually and thus a major public health concern(1). Osteoporosis most often occurs in post-menopausal women; however autoimmune diseases and glucocorticoid treatment are also independent risk factors(2). Glucocorticoids remain the main treatment for giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), and typically at high doses with an extended period of exposure. Prolonged use of glucocorticoids induces a low bone turnover state causing more pronounced impact on the synthesis rather than the resorption, leading to net loss of bone strength(5). Thus, high and prolonged doses of glucocorticoid treatment in GCA/PMR substantially increases the risk of fractures (3,5). Current guidelines for osteoporosis screening for patients on glucocorticoid treatment were published by the American College of Rheumatology (ACR). Nevertheless, rheumatologists and primary care providers often defer responsibility to one another or to other parties, leading to a lack of osteoporosis screening in GCA/PMR patients(5).This project aimed to increase the rate of ordering recommended screening for osteoporosis by at least 10% in patients diagnosed with GCA/PMR within the West Virginia University hospital system who have been treated with high dose glucocorticoids.

Methods: Patients (n=87) diagnosed with GCA/PMR and treated with high dose of glucocorticoids (≥ 7.5 mg of prednisone for greater than 3 months) were identified via chart review from 06/24/2020 to 12/13/2021. All patients with GCA/PMR included in our study met ACR diagnostic criteria. The number of DEXA scans ordered for patients diagnosed with GCA/PMR was measured pre-intervention. The PDSA (plan-do-study-act) model was then used to implement a quality improvement (QI) initiative at the provider level, which included provider education (email and verbal) coupled with an EPIC best practice alert for this specific patient population. The number of DEXA scans ordered was assessed two months after QI implementation in post-intervention patients (n=34).

Results: Only 57.5% of pre-intervention patients (n = 87, 72.6 ± 8.4 years old) had an appropriate screening completed with a DEXA scan. Within two months after QI implementation, the screening rate in post-intervention patients (n=34, 71.4 ± 9.2 years old) increased to 70.6% (p = 0.217).

Conclusion: Screening for osteoporosis is an important preventive measure for GCA/PMR patients, especially those on high doses of glucocorticoids. Our study demonstrates an improvement in DEXA screening rates by 13.1% over a period of two months by implementing reminders and education for providers in both rheumatology clinics and primary care clinics settings. Future implementation could be expanded at the patient level, through education and sending reminders to discuss the appropriateness of osteoporosis screening with their providers.

Supporting image 1

Table 1.


Disclosures: K. Tran: None; E. Sockman: None; R. Salyer: None; M. Young: None; A. Abbasi: None; D. Verma: None.

To cite this abstract in AMA style:

Tran K, Sockman E, Salyer R, Young M, Abbasi A, Verma D. Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/improving-osteoporosis-screening-in-patients-with-polymyalgia-rheumatica-and-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-osteoporosis-screening-in-patients-with-polymyalgia-rheumatica-and-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology